(Q50462637)

14 March 2018

title

Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. (English)

1 reference

14 March 2018

chronic idiopathic myelofibrosis

1 reference

1 reference

1

Ayalew Tefferi

1 reference

14 March 2018

publication date

1 September 2014

1 reference

14 March 2018

American Journal of Hematology

published in

1 reference

14 March 2018

volume

89

1 reference

14 March 2018

issue

9

1 reference

14 March 2018

page(s)

915-925

1 reference

14 March 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

cites work

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

21 January 2018

1 reference

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

Pathogenesis of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

Conventional cytogenetics in myelofibrosis: literature review and discussion

21 January 2018

1 reference

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

21 January 2018

1 reference

Genetics: CALR mutations and a new diagnostic algorithm for MPN.

21 January 2018

1 reference

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

Myelodysplasia with fibrosis: a distinct entity?

21 January 2018

1 reference

Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review

21 January 2018

1 reference

Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia

21 January 2018

1 reference

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

21 January 2018

1 reference

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

21 January 2018

1 reference

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.

21 January 2018

1 reference

Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.

21 January 2018

1 reference

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.

21 January 2018

1 reference

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

21 January 2018

1 reference

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

21 January 2018

1 reference

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

Mutations and prognosis in primary myelofibrosis

21 January 2018

1 reference

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.

21 January 2018

1 reference

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 January 2018

1 reference

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

21 January 2018

1 reference

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

Risk factors for leukemic transformation in patients with primary myelofibrosis

21 January 2018

1 reference

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

21 January 2018

1 reference

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

21 January 2018

1 reference

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

21 January 2018

1 reference

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

21 January 2018

1 reference

Outcome of transplantation for myelofibrosis

21 January 2018

1 reference

New and old treatment modalities in primary myelofibrosis

21 January 2018

1 reference

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

21 January 2018

1 reference

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

21 January 2018

1 reference

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis

21 January 2018

1 reference

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

A phase-2 trial of low-dose pomalidomide in myelofibrosis

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

21 January 2018

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

21 January 2018

1 reference

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

21 January 2018

1 reference

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt

21 January 2018

1 reference

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23703

1 reference

14 March 2018

1 reference

14 March 2018